Compare iShares MSCI Singapore ETF (EWS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Nuwellis Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.79, while Nuwellis Inc trades at $2.85 (market cap $1.10M). The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| EWS | NUWE | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $32.09 | $558.26 |
52-Week Low | $26.47 | $2.80 |
Market Cap | — | $1.10M |
Enterprise Value | — | -$709.83K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.
The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
